Ginkgo biloba and acetazolamide for acute mountain sickness: Exclusion of high risk, low status groups perpetuates discrimination and inequalities

BMJ 2004; 329 doi: 10.1136/bmj.329.7458.171-b (Published 15 July 2004)
Cite this as: BMJ 2004;329:171.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jean Adams (j.m.adams@ncl.ac.uk), research fellow
  1. School of Population and Health Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH

    EDITOR—Gertsch et al report the results of a randomised controlled trial of ginkgo biloba and acetazolamide for acute mountain sickness in trekkers in the Everest region of Nepal.1 However, it is …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL